AustraliaHealth

Neuren Pharmaceuticals (ASX:NEU) highlighted key updates from its partner Acadia Pharmaceuticals' (NASXDAQ:ACAD) presentation at the 44th annual J.P. Morgan Healthcare Conference.

Australian medicinal cannabis leaders Little Green Pharma (ASX:LGP) and Cannatrek have entered into a binding scheme implementation deed, under which LGP will acquire 100% of Cannatrek’s issued capital via a scheme of arrangement.

Argent BioPharma (ASX:RGT) has entered a binding agreement with AusCann Group (ASX:ACN) to acquire AusCann's 48% equity interest in CannPal for $2 million in Argent shares at 10 cents per share.

AVITA Medical (ASX:AVH) reported preliminary unaudited results for the fourth quarter and full year of fiscal 2025, highlighting year-on-year revenue growth, a new US$60 million debt facility, and a positive revenue outlook for 2026.

Entropy Neurodynamics (ASX:ENP) has reported Phase 2a clinical trial results showing that TRP-8802, an oral psilocybin therapy.

Singular Health (ASX:SHG) has announced that the US Food and Drug Administration has granted 510(k) clearance for 3DICOM MD Cloud, the company's cloud-based evolution of its FDA-cleared 3DICOM MD software.

Enlitic (ASX:ENL) has completed technical validation of its Ensight medical imaging data standardisation platform on Oracle Cloud Infrastructure, leveraging AMD EPYC processors.

NeuroScientific Biopharmaceuticals (ASX:NSB) has announced encouraging results from its Special Access Program for patients with fistulising Crohn's disease.

LTR Pharma (ASX:LTP) has commenced patient recruitment for its Phase 2 pharmacokinetic study of SPONTAN, the company's rapid-acting intranasal spray for the treatment of erectile dysfunction, in Australia.

Tetratherix (ASX:TTX) has announced a major clinical milestone for its TetraDerm product, with the completion of the second safety review of the trial’s second cohort.

ReNerve (ASX:RNV), an Australian medical device innovator specialising in peripheral nerve injury solutions, has secured broader listing approval for its NervAlign Nerve Cuff in Hong Kong.

WA medicinal cannabis manufacturer Cannaponics is eyeing an Australian Securities Exchange listing in the second half of this year.